The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | 18-month follow-up on CARTITUDE-1
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, gives an update on the CARTITUDE-1 (NCT03548207) Phase 1b/2 study at 18 months of follow-up. In this trial, ciltacabtagene autoleucel (cilta-cel) was given to patients with relapsed/refractory (R/R) multiple myeloma. Dr Usmani reports an overall response rate among 97 patients of 98% with a stringent complete response (CR) of 80.4%. The median duration of response was 24 months, and has not been reached in patients who achieved stringent CR. The 18-month progression-free survival rate was 66% and the 18-month overall survival was 81%. Dr Usmani comments on the safety profile of cilta-cel, highlighting the benefits of bridging therapy, and outlines other trials investigating the safety and efficacy of cilta-cel in patients with myeloma. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.
